RHJA
SCPH

Rice Hall James & Associates’s scPharmaceuticals SCPH Stock Holding History

Rice Hall James & Associates’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-101,713
Closed -$577K – 252
2025
Q3 		$577K Sell
101,713
-1,370,814
-93% -$7.02M 0.03% 217
2025
Q2 		$5.61M Buy
1,472,527
+74,470
+5% +$231K 0.3% 77
2025
Q1 		$3.68M Buy
1,398,057
+408,422
+41% +$1.33M 0.22% 102
2024
Q4 		$3.5M Buy
989,635
+367,970
+59% +$1.41M 0.19% 124
2024
Q3 		$2.83M Buy
621,665
+124,438
+25% +$602K 0.15% 142
2024
Q2 		$2.16M Buy
497,227
+216,122
+77% +$950K 0.13% 156
2024
Q1 		$1.41M Buy
281,105
+200,101
+247% +$1.12M 0.08% 194
2023
Q4 		$508K Sell
81,004
-6,067
-7% -$34.7K 0.03% 246
2023
Q3 		$620K Buy
87,071
+7,241
+9% +$57.1K 0.04% 234
2023
Q2 		$813K Buy
+79,830
New +$833K 0.05% 226

Rice Hall James & Associates's SCPH Position: Q4 2025 in Review

Rice Hall James & Associates sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 101,713 shares — an estimated $577K sold.

Rice Hall James & Associates first reported a position in SCPH in Q2 2023 and held it in 10 quarters. The position peaked at $5.61M in Q2 2025. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

  • Rice Hall James & Associates reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rice Hall James & Associates sold 101,713 scPharmaceuticals shares in Q4 2025, an estimated $577K.
  • Rice Hall James & Associates first reported a position in scPharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Rice Hall James & Associates's scPharmaceuticals position peaked at $5.61M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Rice Hall James & Associates's 13F filing for Q4 2025, filed 17 Feb 2026.